LTRN
Price
$1.71
Change
-$0.05 (-2.84%)
Updated
Sep 11 closing price
Capitalization
21.86M
60 days until earnings call
Intraday BUY SELL Signals
PMCB
Price
$0.45
Change
+$0.01 (+2.27%)
Updated
Sep 11 closing price
Capitalization
4.83M
Intraday BUY SELL Signals
Interact to see
Advertisement

LTRN vs PMCB

LTRN vs PMCB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
LTRN vs. PMCB commentary
Sep 13, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LTRN is a Hold and PMCB is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LTRN($21.9M) has a higher market cap than PMCB($4.83M). PMCB YTD gains are higher at: -37.845 vs. LTRN (-43.564). PMCB has higher annual earnings (EBITDA): -5.38M vs. LTRN (-15.45M). PMCB has more cash in the bank: 20.5M vs. LTRN (7.36M). LTRN has less debt than PMCB: LTRN (39.7K) vs PMCB (75.2K). LTRN (0) and PMCB (0) have equivalent revenues.
LTRNPMCBLTRN / PMCB
Capitalization21.9M4.83M453%
EBITDA-15.45M-5.38M287%
Gain YTD-43.564-37.845115%
P/E RatioN/A13.74-
Revenue00-
Total Cash7.36M20.5M36%
Total Debt39.7K75.2K53%
FUNDAMENTALS RATINGS
LTRN vs PMCB: Fundamental Ratings
LTRN
PMCB
OUTLOOK RATING
1..100
5170
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
68
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
9188
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
1550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LTRN's Valuation (50) in the null industry is in the same range as PMCB (68). This means that LTRN’s stock grew similarly to PMCB’s over the last 12 months.

LTRN's Profit vs Risk Rating (100) in the null industry is in the same range as PMCB (100). This means that LTRN’s stock grew similarly to PMCB’s over the last 12 months.

PMCB's SMR Rating (96) in the null industry is in the same range as LTRN (100). This means that PMCB’s stock grew similarly to LTRN’s over the last 12 months.

PMCB's Price Growth Rating (88) in the null industry is in the same range as LTRN (91). This means that PMCB’s stock grew similarly to LTRN’s over the last 12 months.

PMCB's P/E Growth Rating (2) in the null industry is significantly better than the same rating for LTRN (100). This means that PMCB’s stock grew significantly faster than LTRN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LTRNPMCB
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
N/A
Bullish Trend about 1 month ago
74%
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
COMPARISON
Comparison
Sep 13, 2026
Stock price -- (LTRN: $1.71 vs. PMCB: $0.45)
Brand notoriety: LTRN and PMCB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LTRN: 97% vs. PMCB: 50%
Market capitalization -- LTRN: $21.86M vs. PMCB: $4.83M
LTRN [@Biotechnology] is valued at $21.86M. PMCB’s [@Biotechnology] market capitalization is $4.83M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.64B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LTRN’s FA Score shows that 0 FA rating(s) are green while PMCB’s FA Score has 1 green FA rating(s).

  • LTRN’s FA Score: 0 green, 5 red.
  • PMCB’s FA Score: 1 green, 4 red.
According to our system of comparison, both LTRN and PMCB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LTRN’s TA Score shows that 3 TA indicator(s) are bullish while PMCB’s TA Score has 4 bullish TA indicator(s).

  • LTRN’s TA Score: 3 bullish, 5 bearish.
  • PMCB’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, PMCB is a better buy in the short-term than LTRN.

Price Growth

LTRN (@Biotechnology) experienced а -10.24% price change this week, while PMCB (@Biotechnology) price change was -7.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.09%. For the same industry, the average monthly price growth was -3.45%, and the average quarterly price growth was +2531.70%.

Reported Earning Dates

LTRN is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-6.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
LTRN
Daily Signal:
Gain/Loss:
PMCB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WES49.030.84
+1.74%
Western Midstream Partners LP
LEGH27.670.18
+0.65%
Legacy Housing Corp
PYPD5.15-0.01
-0.19%
PolyPid Ltd
BKU44.78-0.39
-0.86%
Bankunited
NIKI5.70-0.57
-9.09%
Niki BioSolutions Inc

PMCB and

Correlation & Price change

A.I.dvisor tells us that PMCB and FATE have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PMCB and FATE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PMCB
1D Price
Change %
PMCB100%
+2.06%
FATE - PMCB
33%
Poorly correlated
-0.86%
CAPR - PMCB
31%
Poorly correlated
+0.84%
LTRN - PMCB
31%
Poorly correlated
-2.84%
IMTX - PMCB
30%
Poorly correlated
+0.46%
KZIA - PMCB
29%
Poorly correlated
+1.63%
More